Latest market price
11.82
+0.00%
NEOGQT77Neogen Corporation·NASDAQ
11.82+0.00%
TA
Loading chart...
Screen all →
Snapshot
Index—P/E—EPS (ttm)-0.25Insider Own3.27%Shs Outstand218.31MPerf Week-3.19%
Market Cap2.58BForward P/E26.66EPS next Y0.44Insider Trans0.01%Shs Float216.15MPerf Month-2.72%
Enterprise Value3.18BPEG—EPS next Q0.07Short Float5.52%Perf Quarter0.08%
Income-56.00MP/S2.92EPS this Y16.28%Short Ratio3.65Perf Half Y30.03%
Sales884.00MP/B1.24EPS next Y33.00%ROA-1.70%Short Interest11.93MPerf YTD69.10%
Book/sh9.56P/C15.00EPS next 5Y12.82%ROE-2.68%52W High14.26 -17.11%Perf Year97.00%
Cash/sh0.79P/FCF51.61EPS past 3/5Y—ROIC-0.19%52W Low5.37 120.11%Perf 3Y-23.64%
Dividend Est.—EV/EBITDA30.31Sales past 3/5Y1.91% 13.20%Gross Margin47.40%Volatility4.10% 5.03%Perf 5Y-71.63%
Dividend TTM—EV/Sales3.60EPS Y/Y TTM—Oper. Margin-0.83%ATR (14)0.53Perf 10Y-39.51%
Dividend Ex-Date—Quick Ratio2.92Sales Y/Y TTM-0.23%Profit Margin-6.35%RSI (14)45.25Recom2.64
Dividend Gr. 3/5Y—Current Ratio3.90EPS Q/Q—SMA20-1.15%Beta1.84Target Price13.50
Payout0.00%Debt/Eq0.37Sales Q/Q6.70%SMA50-3.30%Rel Volume0.85Prev Close11.82
Employees2,636LT Debt/Eq0.37EarningsJan 14SMA20013.32%Avg Volume3.29MPrice11.82
IPO DateAug 23, 1989Option/ShortYes / YesEPS/Sales Surpr.50.00% 7.03%Net Debt/EBITDA5.73Volume2,797,642Change0.00%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-30-26ReiteratedGuggenheimBuy$12 → $14
Aug-26-26UpgradePiper SandlerNeutral → Overweight
Aug-03-26ReiteratedPiper SandlerNeutral$10 → $13
Jan-12-26ReiteratedPiper SandlerNeutral$6.50 → $10
Jan-09-26ReiteratedGuggenheimBuy$12
Dec-10-25UpgradeCJS SecuritiesMarket Perform → Market Outperform
Oct-16-25ReiteratedPiper SandlerNeutral$5.00 → $6.50
Jul-29-25DowngradeWilliam BlairOutperform → Market Perform
Apr-22-25ReiteratedPiper SandlerNeutral$18 → $5.00
Aug-06-24ReiteratedPiper SandlerNeutral$17 → $18
Latest News· Times ET
Oct-30-26
Oct-27-26
Oct-23-26
Oct-22-26
Oct-20-26
Oct-19-26
Oct-15-26
Oct-14-26
Oct-13-26
Oct-12-26
Oct-09-26
Oct-08-26
Company

Neogen Corporation, including its affiliated companies, is a global leader in creating, manufacturing, and distributing a wide range of products crucial for maintaining food quality and animal health. The enterprise is structured into two primary divisions: Food Safety and Animal Safety. The Food Safety segment delivers advanced diagnostic test kits and associated solutions to identify detrimental or unintended contaminants in food and animal feed. This extensive detection capability covers threats such as foodborne pathogens, spoilage-causing organisms, naturally occurring toxins, food allergens, genetically modified ingredients, ruminant by-products, specific meat identification, residual drugs and pesticides, and overall sanitation issues. A key product is the AccuPoint Advanced rapid sanitation test, which quickly spots adenosine triphosphate (ATP), indicating the presence of living cells, to verify cleanliness. Customers for this segment are diverse, encompassing producers and processors of food and feed, grain operations, manufacturers of processed foods like cookies, crackers, candy, and ice cream, as well as those handling meat, poultry, seafood, fruits, vegetables, and dairy. It also serves laboratories and producers of pharmaceuticals, cosmetics, and veterinary vaccines. The Animal Safety division provides a comprehensive portfolio for the animal health market. Offerings include veterinary instruments, pharmaceuticals, vaccines, topical medications, parasiticides, diagnostic products, rodenticides, cleaning agents, disinfectants, insecticides, and genomics testing services. This segment also supplies specialized products for researchers investigating biologically active substances. Its immunoassay test kits are vital for detecting illicit and therapeutic drugs in farm and racing animals, identifying drug residues in meat and meat products, and assisting in human forensic toxicology drug screenings. Moreover, products from this division are instrumental in upholding hygienic conditions and minimizing the risks posed by bacteria, fungi, and viruses. Neogen Corporation was established in 1981 and is headquartered in Lansing, Michigan.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2026
5/31/2026
FY 2025
5/31/2025
FY 2024
5/31/2024
FY 2023
5/31/2023
FY 2022
5/31/2022
FY 2021
5/31/2021
FY 2020
5/31/2020
FY 2019
5/31/2019
Total Revenue884870895924—————
Cost of Goods Sold Incl. D&A465462473462—————
Gross Profit420409421463—————
Selling, General and Administrative Excl. Other407412402383—————
Research and Development21182122—————
Other Operating Expense-20-11-20—————
Operating Income-7-22977—————
Interest Expense57587273—————
Unusual Expense
—————————
Non-Operating Income (Expense)-370-1,071-18—————
Net Income Before Taxes-67-9-1,133-14—————
Income Taxes-11-1-41-5—————
Consolidated Net Income-56-8-1,092-9—————
Net Income From Continuing Operations-56-8-1,092-9—————
Net Income-56-8-1,092-9—————
EPS (Recurring)-0.25-0.04-5.03-0.04—————
EPS (Basic, Before Extraordinaries)-0.25-0.04-5.03-0.04—————
EPS (Diluted)-0.25-0.04-5.03-0.04—————
EBITDA105165-938183—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio2.912.251.423.07—————
Gross Margin47.5147.0147.0450.11—————
Operating Margin-0.79-2.531.018.33—————
Net Margin-6.33-0.92-122.01-0.97—————
Shares Outstanding218218217216—————
Market Capitalization2,5771,9551,2722,840—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$15.29$12.46$9.63$6.79$3.96● Close Price0.00K1.51K3.02K4.53K6.04KUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
BOREL JAMES CDirectorOct 29 '26Option Exercise12.211,77621,685106,737Oct 30
Green Ronald DDirectorOct 29 '26Option Exercise12.211,77621,68529,044Oct 30
CAPELLO JEFFREY DDirectorOct 29 '26Option Exercise12.211,77621,68542,892Oct 30
Woteki Catherine EDirectorOct 29 '26Option Exercise12.211,77621,68529,507Oct 30
Hastings Gregory SVP, Animal HealthOct 29 '26Option Exercise12.211,21114,78633,786Oct 30
RODRIGUEZ RAFAEL ADirectorOct 29 '26Option Exercise12.211,77621,68531,211Oct 30
Gupta AashimaDirectorOct 29 '26Option Exercise12.211,77621,68538,180Oct 30
Hastings Gregory SVP, Animal HealthOct 14 '26Option Exercise12.002873,44432,655Oct 23
Nassif MikhealCEOOct 09 '26Buy11.955056,0351,579Oct 09
Nassif MikhealCEOAug 04 '26Buy11.813704,3701,074Aug 06
Rocklin Amy MFormer Chief Legal OfficerMay 18 '26Option Exercise9.2935,183326,85092,423May 19
Moylan John PatrickChief Accounting OfficerMay 04 '26Option Exercise9.534,55843,43818,905May 05
Nassif MikhealCEOFeb 17 '26Buy10.9423252704Feb 17
Nassif MikhealCEOFeb 02 '26Buy10.0024240681Feb 02
Nassif MikhealCEOJan 26 '26Buy9.8625246657Feb 02
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.